ANI Pharmaceuticals (ANIP) Stock Forecast & Price Target

Compare

334 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ANIP Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

ANI

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ANIP Stock 12 Month Forecast

Average Price Target

$110.80

▲(36.62% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for ANI Pharmaceuticals in the last 3 months. The average price target is $110.80 with a high forecast of $121.00 and a low forecast of $100.00. The average price target represents a 36.62% change from the last price of $81.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"54":"$54","71":"$71","88":"$88","105":"$105","122":"$122"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$110.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[54,71,88,105,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.47,87.28,90.09,92.9,95.71,98.52,101.33,104.14,106.95,109.75999999999999,112.57,115.38,118.19,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.47,86.49538461538461,88.52076923076923,90.54615384615384,92.57153846153847,94.59692307692308,96.62230769230769,98.64769230769231,100.67307692307692,102.69846153846154,104.72384615384615,106.74923076923076,108.77461538461537,{"y":110.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.47,85.66461538461539,86.85923076923076,88.05384615384615,89.24846153846154,90.44307692307692,91.6376923076923,92.8323076923077,94.02692307692308,95.22153846153846,96.41615384615385,97.61076923076922,98.80538461538461,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$121.00

Average Price Target$110.80

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Glen Santangelo

Barclays

$100

Buy

23.30%

Upside

Initiated

12/08/25

Barclays Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)

Les Sulewski

Truist Financial

―

Hold

―

Reiterated

11/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), ANI Pharmaceuticals (NASDAQ: ANIP) and Summit Therapeutics (NASDAQ: SMMT)

Brandon Folkes

H.C. Wainwright

$121

Buy

49.20%

Upside

Reiterated

11/10/25

ANI Pharmaceuticals: Strong Commercial Execution and Promising Growth Prospects Reinforce Buy Rating

Vamil Divan

Guggenheim

$114→$115

Buy

41.80%

Upside

Reiterated

11/09/25

ANI Pharmaceuticals price target raised to $115 from $114 at GuggenheimANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim

Faisal Khurshid

Leerink Partners

$100→$103

Buy

27.00%

Upside

Reiterated

10/15/25

Leerink Partners Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)Leerink Partners analyst Faisal A. Khurshid raised the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $103.00 (from $100.00) while maintaining a Outperform rating.

Ekaterina Knyazkova

J.P. Morgan

$95→$115

Buy

41.80%

Upside

Reiterated

09/24/25

Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion

David Amsellem

Piper Sandler

$80→$94

Buy

15.91%

Upside

Reiterated

08/08/25

ANI Pharmaceuticals price target raised to $94 from $80 at Piper SandlerANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler

Gary Nachman

Raymond James

$64.66→$86

Buy

6.04%

Upside

Reiterated

06/20/25

Raymond James Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Glen Santangelo

Barclays

$100

Buy

23.30%

Upside

Initiated

12/08/25

Barclays Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)

Les Sulewski

Truist Financial

―

Hold

―

Reiterated

11/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), ANI Pharmaceuticals (NASDAQ: ANIP) and Summit Therapeutics (NASDAQ: SMMT)

Brandon Folkes

H.C. Wainwright

$121

Buy

49.20%

Upside

Reiterated

11/10/25

ANI Pharmaceuticals: Strong Commercial Execution and Promising Growth Prospects Reinforce Buy Rating

Vamil Divan

Guggenheim

$114→$115

Buy

41.80%

Upside

Reiterated

11/09/25

ANI Pharmaceuticals price target raised to $115 from $114 at GuggenheimANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim

Faisal Khurshid

Leerink Partners

$100→$103

Buy

27.00%

Upside

Reiterated

10/15/25

Ekaterina Knyazkova

J.P. Morgan

$95→$115

Buy

41.80%

Upside

Reiterated

09/24/25

Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion

David Amsellem

Piper Sandler

$80→$94

Buy

15.91%

Upside

Reiterated

08/08/25

ANI Pharmaceuticals price target raised to $94 from $80 at Piper SandlerANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler

Gary Nachman

Raymond James

$64.66→$86

Buy

6.04%

Upside

Reiterated

06/20/25

Raymond James Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)

Stocks with the Highest Top Analyst Consensus in the Sector

Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ANI Pharmaceuticals

1 Month

xxx

Success Rate

5/8 ratings generated profit

Average Return

+10.25%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +10.25% per trade.

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+15.15%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +15.15% per trade.

1 Year

Faisal KhurshidLeerink Partners

Success Rate

7/8 ratings generated profit

Average Return

+25.35%

reiterated a buy rating 2 months ago

Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +25.35% per trade.

2 Years

xxx

Success Rate

7/8 ratings generated profit

Average Return

+25.12%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +25.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANIP Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ANIP has received 4 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ANIP average Analyst price target in the past 3 months is 110.80.

Each month's total comprises the sum of three months' worth of ratings.

ANIP Financial Forecast

ANIP Earnings Forecast

Next quarter’s earnings estimate for ANIP is $1.98 with a range of $1.67 to $2.09. The previous quarter’s EPS was $2.04. ANIP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year ANIP has Performed in-line its overall industry.

ANIP Sales Forecast

Next quarter’s sales forecast for ANIP is $233.32M with a range of $229.70M to $242.14M. The previous quarter’s sales results were $227.81M. ANIP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year ANIP has Performed in-line its overall industry.

ANIP Stock Forecast FAQ

What is ANIP’s average 12-month price target, according to analysts?

Based on analyst ratings, ANI Pharmaceuticals Inc’s 12-month average price target is 110.80.

What is ANIP’s upside potential, based on the analysts’ average price target?

ANI Pharmaceuticals Inc has 36.62% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ANIP a Buy, Sell or Hold?

ANI Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is ANI Pharmaceuticals Inc’s price target?

The average price target for ANI Pharmaceuticals Inc is 110.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $121.00 ,the lowest forecast is $100.00. The average price target represents 36.62% Increase from the current price of $81.1.

What do analysts say about ANI Pharmaceuticals Inc?

ANI Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ANIP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

ANI Pharmaceuticals (ANIP) Stock Forecast & Price Target

ANIP Analyst Ratings

ANIP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ANI Pharmaceuticals

ANIP Analyst Recommendation Trends

ANIP Financial Forecast

ANIP Earnings Forecast

ANIP Sales Forecast

ANIP Stock Forecast FAQ

Detailed List of Analyst Forecasts